[{"orgOrder":0,"company":"Amniox Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amniox Announces Initiation for First of Two Phase 3 Clinical Trials of Cryopreserved Umbilical Cord TTAX01 Allograft","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase III"},{"orgOrder":0,"company":"PolarityTE","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PolarityTE Announces Positive Top-Line Data from Interim Analysis of SkinTE\u2122 Diabetic Foot Ulcer Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"July 2020","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Undisclosed"},{"orgOrder":0,"company":"Centaur Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Centaur Pharma Launches Novel Topical Solution WoxHeal for the Treatment of Diabetic Foot Ulcer","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Approved"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Advances Planned Clinical Trial in Diabetic Foot Ulcers in MoU With TekCyte","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Preclinical"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ethics Approval for Cynata\u2019s Clinical Trial in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Preclinical"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Aurealis Therapeutics","sponsor":"Xbiome","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Lakewood-Amedex","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lakewood-Amedex Enrolls First Patient in Phase 2 Clinical Trial for Patients with Chronic Diabetic Foot Ulcers (cDFU)","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Promore Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Peptide","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Phase II"},{"orgOrder":0,"company":"MiMedx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MIMEDX EPIFIX\u00ae Receives Reimbursement Approval in Japan","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Approved"},{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cell Research Corporation (CRC) Announces Positive Results of Phase I Study for CorLiCyte\u00ae","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"SINGAPORE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I"},{"orgOrder":0,"company":"MiMedx","sponsor":"Gunze Medical Limited","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MIMEDX Announces Commercial Launch of EPIFIX\u00c2\u00ae in Japan with Exclusive Distribution Agreement with Gunze Medical Limited","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Approved"},{"orgOrder":0,"company":"Microbion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Microbion Corporation Initiates Phase 2 Clinical Study Evaluating Topical Pravibismane Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech Announces FDA 510(k) Clearance for its coactiv+\u2122 Antimicrobial Wound Gel","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Approved"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Molnlycke Health Care AB","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with M\u00f6lnlycke on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Doses Patients in Phase I\/II Clinical Trial of RECCE 327 for Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"3M Health Care","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with 3M on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kane Biotech and ProgenaCare Global Launch Newly Rebranded Revyve\u2122 Antimicrobial Wound Gel at Advanced Wound Care Fall Forum","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Approved"},{"orgOrder":0,"company":"MediWound","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MediWound Announces Positive Topline Results from its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"MiMedx","sponsor":"MediWound","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MediWound Announces Collaboration with MIMEDX on EscharEx\u00ae Phase III Study","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Innocan Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Innocan Pharma Announces Promising Successful Results in Efficacy Trial of Diabetic Foot Relief Treatment","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Preclinical","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Preclinical"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Announces Expansion of Phase I\/II Trial of RECCE\u00ae 327 for the Treatment of Diabetic Foot Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I\/ Phase II","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Cynata Therapeutics Completes Patient Enrolment in Phase 1 Trial of CYP-006TK in Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Phase I"},{"orgOrder":0,"company":"Discovery Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Discovery Therapeutics Caribe Receives Study May Proceed Letter from FDA to Initiate a Phase 3 Clinical Trial of Intralesional rhEGF for the Treatment of Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Peptide","graph2":"Phase II"},{"orgOrder":0,"company":"Rion","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RION Announces First Patient Dosed in Phase 2 Clinical Study of Purified Exosome Product\u2122 for Diabetic Foot Ulcers","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Phase II"},{"orgOrder":0,"company":"Recce Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Recce Pharmaceuticals Expands RECCE\u00ae 327 Gel Trials for Skin Infections","therapeuticArea":"Podiatry","highestDevelopmentStatus":"Phase I","country":"AUSTRALIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Phase I"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria. It is under development for the treatment of acute bacterial skin and skin structure infections.
Purified Exosome Product, designed to promote cell growth and formation of new blood vessels, while also reducing inflammation and protecting cells, is being investigated for diabetic foot ulcer.
rhEGF (recombinant human epidermal growth factor) is a 53 amino acid polypeptide isolated for the first time from mice submaxillary glands. It is being evaluated for the treatment of complex and complicated refractory neuropathic, ischemic, and neuroischemic diabetic foot ulcers.
Lead Product(s):
Recombinant Human Epidermal Growth Factor
CYP-006TK is a topical wound dressing, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with diabetic foot ulcers.
RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
CYP-006TK is allogenic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs) or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing. It is being evaluated for the treatment of diabetic foot ulcer.
revyve™ Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), 1st and 2nd degree burns, partial & full thickness wounds, large surface area wounds and surgical incisions for adult populations.
EscharEx (EX-02) is being evaluated for efficacy and safety in the debridement of chronic wounds, with the first indication being VLUs. During debridement phase, 3M’s two-layer compression systems will be used as soc in all study arms, until the wounds reach complete healing.
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for Diabetic Foot Infections.
Under the collaboration, Mölnlycke will provide Mepilex® Up, its most recent line extension to its global market leading brand, along with Exufiber® and Exufiber® Ag dressings to be used during MediWound's upcoming Phase III study of EscharEx (EX-02) in venous leg ulcers.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
